News Share- Gongwin-KY Completed Case Acceptance for Canine/Cat Field Pre-Trial
February 02, 2021 Independence Evening Post
[Report by reporter An-Tsung Ko in Taipei]
Gongwin Biopharm Co., Ltd. (Gongwin-KY, 6617), which is currently implementing PTS100 Phase II liver cancer clinical trial at National Taiwan University Hospital, Taipei Veterans General Hospital, and Taipei Medical University Hospital, has entered the blue ocean market of "Canine/Cat Companion Animal Cancer Treatment". The case acceptance of 22 dog/cat companion animals was completed for the " field pre-trial" approved by the Council of Agriculture, including 6 animals suffering from melanoma, 2 soft tissue sarcomas, 2 squamous cell carcinoma, 2 lipomas, 1 mast cell tumor and other diseases. Excellent remission effects were achieved.
Gongwin-KY stated that, in regards to the results of "canine/cat companion animal cancer treatment", the Company would duplicate the practice of holding a meeting on the conclusion of human clinical trials by inviting clinical veterinarians participating in the trial to share the treatment results of GWA101 new anti-cancer animal drug after the trial is concluded. The case conclusion report along with the field trial plan would be submitted to the Council of Agriculture for a formal field trial application, so as to move forward to obtain a new drug certificate for animal anti-cancer drug.
The institutional investors pointed out that, based on the estimation in "Pet Cancer Therapeutics Market—Growth, Trends, and Forecast (2019-2024)" report published by ResearchandMarkets in November 2019, the total market value of the American pet health care market would reach US$ 75.38 billion in 2019. Among them, cancer treatment for companion dogs would be the biggest market trend setter in the next 5 years. In order to seize this global market opportunity, Gongwin-KY has filed American patent applications for melanoma and lipoma in 2020, which would advance the deployment of international licensing opportunities for future GWA101 new anti-cancer drugs. In addition, Toluene Sulfonamide injection for the treatment of lung cancer also passed the clinical trial review in 2019 as well as the drug/toxicology review at the end of 2020. The review of pharmacy (chemical/manufacturing/control) is still in progress. In the future, the target would be on the global niche market for central lung cancer severe airway obstruction.
Gongwin-KY is optimistic that its series of new anti-cancer drug product lines will have major progress this year. In addition to the aforementioned projects, PTS-02 for adenoid cystic carcinoma and PTS500 for malignant pleural effusion have both been granted patent certificates in many countries. The Company will file clinical trial applications in the future, so as to create a complete global deployment of PTS anti-cancer new drugs and make future overall operational contributions.
https://news.campaign.yahoo.com.tw/lung-health/arti.php?id=ce0711e8-91ba-35b4-96de-9fa520287880
News&Media